Verrica

We are focused on changing the narrative around skin diseases and making treatment a more efficient process for both physicians and patients. On July 21, 2023, Verrica’s lead product, YCANTH™ (cantharidin) topical solution 0.7%, became the first treatment approved by the FDA to treat adult and pediatric patients as young as two years of age with molluscum contagiosum, a highly contagious, viral skin disease infection affecting approximately 6 million people in the United States, primarily children.